Page last updated: 2024-12-10

an-1792

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID3029491
CHEMBL ID16987
SCHEMBL ID79464
MeSH IDM0403046

Synonyms (9)

Synonym
CHEMBL16987
an-1792 ,
SCHEMBL79464
.alpha.-((sec-butylamino)methyl)-5,6,7,8-tetrahydro-2-naphthalenemethanol hydrochloride
butidrine hydrochloride [mi]
2-naphthalenemethanol, 5,6,7,8-tetrahydro-.alpha.-(((1-methylpropyl)amino)methyl)-, hydrochloride (1:1)
DTXSID30934006
2-[(butan-2-yl)amino]-1-(5,6,7,8-tetrahydronaphthalen-2-yl)ethan-1-ol--hydrogen chloride (1/1)
Q27251159

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Treatment-related adverse events were reported in 19 (23."( Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD.
Bayer, AJ; Bullock, R; Donoghue, S; Jenkins, L; Jones, RW; Millais, SB; Paterson, KR; Wilkinson, D, 2005
)
0.33
" Together, these serious adverse reactions emphasize the need to test potential Alzheimer's immunotherapy in large cohorts of primate models prior to, or at least concurrently with, human trials, as no effective therapy exists for the disease."( New directions towards safer and effective vaccines for Alzheimer's disease.
Goñi, F; Sigurdsson, EM, 2005
)
0.33

Dosage Studied

ExcerptRelevanceReference
" Dosing was terminated after four early reports of meningoencephalitis, but follow-up continued."( Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization.
Boada, M; Dartigues, JF; Dubois, B; Eisner, L; Flitman, S; Frank, A; Gilman, S; Hock, C; Jouanny, P; Kirby, LC; Laurent, B; Michel, BF; Orgogozo, JM; Puel, M, 2003
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID47945Beta-adrenoceptor blocking potency in cat as dose causing 50% inhibition of the tachycardia produced by 0.2 ug/kg iv of isoproterenol1980Journal of medicinal chemistry, Feb, Volume: 23, Issue:2
Beta-adrenergic blocking agents. 19. 1-Phenyl-2-[[(substituted-amido)alkyl]amino]ethanols.
AID176310Beta-adrenoceptor blocking potency was estimated in vivo by blockade of the isoproterenol tachycardia response in rat; ND means no data1980Journal of medicinal chemistry, Feb, Volume: 23, Issue:2
Beta-adrenergic blocking agents. 19. 1-Phenyl-2-[[(substituted-amido)alkyl]amino]ethanols.
AID48538Percentage inhibition of depressor response in cat was determined1980Journal of medicinal chemistry, Feb, Volume: 23, Issue:2
Beta-adrenergic blocking agents. 19. 1-Phenyl-2-[[(substituted-amido)alkyl]amino]ethanols.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (62)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (1.61)18.7374
1990's0 (0.00)18.2507
2000's42 (67.74)29.6817
2010's17 (27.42)24.3611
2020's2 (3.23)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.37

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.37 (24.57)
Research Supply Index4.26 (2.92)
Research Growth Index4.05 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.37)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (7.69%)5.53%
Reviews33 (50.77%)6.00%
Case Studies2 (3.08%)4.05%
Observational0 (0.00%)0.25%
Other25 (38.46%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]